EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Patient Journey, Disease Burden, Treatment Patterns, and the Impact of Delayed Diagnosis Among Patients With Sjögren's Disease: A Real‐World US Survey

Anjana Lalla, Antton Egana, Jack Milligan, Nicola Massey, James Haughton

ACR Open Rheumatology · 2026-10 · 8 (10)

DOI: 10.1002/acr2.90143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 24.09.2026. Verfasst von Anjana Lalla und 4 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this study was to investigate disease burden, treatment patterns, and impact of delayed diagnosis on patient outcomes in Sjögren's disease (SjD) in a real‐world setting in the United States.

Methods

Data were drawn from the Adelphi Primary Sjögren's Syndrome Disease Specific Programme, a US‐based cross‐sectional collaborative survey between rheumatologists and their next six consecutive consulting patients with SjD. Rheumatologists provided patients’ demographic and clinical information using medical records and a patient‐completed questionnaire.

Results

Rheumatologists (N = 84) provided data on 511 patients with SjD. Calculated Clinical EULAR Sjögren's Syndrome Disease Activity Index (ClinESSDAI)–proxy scores (ps) indicated that patients had mild (44.2%), moderate (30.9%), or severe (24.9%) disease. Among 297 patients, 33.7% had a EULAR Sjögren's Syndrome Patient‐Reported Index (ESSPRI)‐ps of ≥5. Descriptive trends in patient‐reported EuroQoL 5‐Dimension 3‐Level (EQ‐5D‐3L) utility, EuroQoL Visual Analog Scale (EQ‐VAS), Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT‐F), and Work Productivity and Activity Impairment questionnaire scores suggested worsening impairment with increasing SjD severity. Mean (±SD) time to diagnosis was 2.3 (±5.6) years. EQ‐5D‐3L utility ( P = 0.042), EQ‐VAS ( P = 0.026), FACIT‐F ( P = 0.007) scores, and ESSPRI‐ps ( P = 0.001) differed significantly by duration of diagnostic delay. The odds of ClinESSDAI‐ps and ESSPRI‐ps ≥5 at data collection were 2.3 and 2.1 times greater, respectively, in patients diagnosed >12 versus

Autor:innen und Institutionen

  • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Adelphi Real World, Bollington, United Kingdom.

Förderung

  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Lalla, A., Egana, A., Milligan, J., Massey, N., & Haughton, J. (2026). Patient Journey, Disease Burden, Treatment Patterns, and the Impact of Delayed Diagnosis Among Patients With Sjögren's Disease: A Real‐World US Survey. ACR Open Rheumatology, 8(10). https://doi.org/10.1002/acr2.90143

Vancouver

Lalla A, Egana A, Milligan J, Massey N, Haughton J. Patient Journey, Disease Burden, Treatment Patterns, and the Impact of Delayed Diagnosis Among Patients With Sjögren's Disease: A Real‐World US Survey. ACR Open Rheumatology. 2026;8(10). doi:10.1002/acr2.90143

BibTeX
@article{Lalla2026,
  author = {Lalla, Anjana and Egana, Antton and Milligan, Jack and Massey, Nicola and Haughton, James},
  title = {Patient Journey, Disease Burden, Treatment Patterns, and the Impact of Delayed Diagnosis Among Patients With Sjögren's Disease: A Real‐World US Survey},
  journal = {ACR Open Rheumatology},
  year = {2026},
  volume = {8},
  number = {10},
  doi = {10.1002/acr2.90143}
}
Kostenlos starten →